Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia

Abstract

<b>Aim:</b> A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. <b>Patients & methods:</b> Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). <b>Results:</b> Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). <b>Conclusion:</b> Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.